Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ANI Pharmaceuticals, Inc. (ANIP) vs Prestige Consumer Healthcare Inc. (PBH)

ANI Pharmaceuticals, Inc. and Prestige Consumer Healthcare Inc. are both Drug Manufacturers Specialty & Generic companies. Prestige Consumer Healthcare Inc. is the larger, with a market value of $2.2B against $1.7B — 1.3× the size. Prestige Consumer Healthcare Inc. trades at the lower P/E: 13.0× against 15.3×. ANI Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 30.9% against −1.36%. Prestige Consumer Healthcare Inc. has the higher net margin (15.6% vs 11.0%) and the lower return on invested capital (4.70% vs 11.3%). Across the 22 metrics below, ANI Pharmaceuticals, Inc. leads on 14 and Prestige Consumer Healthcare Inc. on 8.

Valuation

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
P/E 15.32 12.98 20.14
P/S 1.60 2.00 2.25
P/B 2.62 1.15 1.90
Price to free cash flow 9.35 9.40 16.54
EV/EBITDA 7.62 12.82 12.29
EV/Sales 1.84 3.76 2.56
Earnings yield 6.53% 7.70% (2.99%)
Free cash flow yield 10.70% 10.64% 0.00%

Profitability

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
Gross margin 60.40% 53.53% 53.94%
Operating margin 15.37% 26.26% 0.00%
Net margin 11.04% 15.57% 0.00%
Free cash flow margin 17.12% 21.30% 0.00%
Return on equity 20.88% 9.12% (0.40%)
Return on assets 7.61% 4.30% (3.32%)
Return on invested capital 11.30% 4.70% 0.00%

Growth

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 30.90% (1.36%) 10.01%
EPS growth (last fiscal year) 419.23% (8.86%) —
Revenue growth, 5-year CAGR 33.48% 2.91% 6.74%
Net income growth, 5-year CAGR 0.00% 2.93% 0.00%

Health

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
Debt to equity 1.02 1.06 0.05
Current ratio 2.91 3.23 2.31
Net debt to EBITDA 1.59 2.77 0.85

Dividend

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ANIP PBH Drug Manufacturers Specialty & Generic median
Market cap 1.70b 2.16b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack